An open‐label, multi‐centre, post‐marketing study to assess the efficacy and safety of a plasma‐derived VWF/FVIII concentrate in patients with von Willebrand disease-Reference-Cited by-同舟云学术

An open‐label, multi‐centre, post‐marketing study to assess the efficacy and safety of a plasma‐derived VWF/FVIII concentrate in patients with von Willebrand disease

Published:2023-11-29 Issue:1 Volume:30 Page:236-240
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Miesbach Wolfgang¹^ORCID,Halimeh Susan²^ORCID,Platokouki Helen³,Podolak‐Dawidziak Maria⁴,Zdziarska Joanna⁵^ORCID,Korczowski Bartosz⁶,Chowdary Pratima⁷^ORCID,Austin Steve⁸,Millar Carolyn⁹,Alamelu Jayanthi¹⁰,Rogosch Tobias¹¹^ORCID,Pabinger Ingrid¹²^ORCID

Affiliation:

1. Haemophilia Centre, Medical Clinic II, Institute of Transfusion Medicine Goethe University Hospital Frankfurt am Main Germany

2. Coagulation Research Center Duisburg Germany

3. “Aghia Sophia” Children's Hospital Athens Greece

4. Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation Medical University of Wroclaw Wroclaw Poland

5. Department of Haematology University Hospital Jagiellonian University Medical College Cracow Poland

6. Department of Pediatrics Institute of Medical Sciences, Medical College University of Rzeszow Rzeszow Poland

7. Katharine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK

8. St George's Healthcare NHS Trust Haemophilia Centre London UK

9. Imperial College, London UK and Imperial College Healthcare NHS Trust London UK

10. Children's Haemophilia Centre Evelina London Children's Hospital London UK

11. CSL Behring Marburg Germany

12. Medical University of Vienna Vienna Austria

Funder

CSL Behring

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14868

Reference11 articles.

1. von Willebrand Disease: A Concise Review and Update for the Practicing Physician

2. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)

3. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE®in patients with von Willebrand’s disease: a prospective multi-centre study

4. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate�) in patients with von Willebrand disorder requiring invasive or surgical procedures

5. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?;Expert Opinion on Pharmacotherapy;2024-07-23